Precision BioSciences, Inc. (NASDAQ:DTIL) Insider J. Jefferson Smith Sells 10,287 Shares

Precision BioSciences, Inc. (NASDAQ:DTIL) insider J. Jefferson Smith sold 10,287 shares of the firm’s stock in a transaction on Wednesday, January 22nd. The shares were sold at an average price of $4.79, for a total value of $49,274.73. Following the sale, the insider now directly owns 87,440 shares of the company’s stock, valued at $418,837.60. This represents a 10.53 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Precision BioSciences Stock Up 9.0 %

DTIL opened at $4.97 on Thursday. The stock has a fifty day moving average of $5.62 and a 200-day moving average of $8.04. The company has a market capitalization of $38.12 million, a P/E ratio of 82.85 and a beta of 1.51. Precision BioSciences, Inc. has a fifty-two week low of $3.61 and a fifty-two week high of $19.43. The company has a debt-to-equity ratio of 0.34, a quick ratio of 9.22 and a current ratio of 9.22.

Analysts Set New Price Targets

A number of research analysts recently commented on DTIL shares. BMO Capital Markets upgraded shares of Precision BioSciences from a “market perform” rating to an “outperform” rating and set a $34.00 price target on the stock in a research note on Friday, January 10th. HC Wainwright reaffirmed a “buy” rating and issued a $60.00 target price on shares of Precision BioSciences in a research report on Friday, January 10th.

Institutional Trading of Precision BioSciences

An institutional investor recently raised its position in Precision BioSciences stock. Geode Capital Management LLC increased its holdings in Precision BioSciences, Inc. (NASDAQ:DTIL) by 40.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 65,974 shares of the company’s stock after buying an additional 19,088 shares during the period. Geode Capital Management LLC owned 0.86% of Precision BioSciences worth $591,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 37.99% of the company’s stock.

About Precision BioSciences

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.